LG190155

LG190155 is a nonsteroidal vitamin D receptor (VDR) agonist. LG190155 activates VDR in mesenchymal stem cells, thereby upregulating the BMP6-IL6 autocrine axis. Pretreatment of mesenchymal stem cells with LG190155 significantly enhances their ability to induce differentiation of acute myeloid leukemia cells, without inducing hypercalcemia. LG190155 is applicable to research related to acute myeloid leukemia (AML)^[1]. In Vitro:Treatment of human umbilical cord mesenchymal stem cells (LMSC) with LG190155 (2-8 µM, 24 h) enhances the ability of LMSC to induce differentiation of AML cells, and this effect is not caused by the cytotoxicity of LG190155 itself against MSC^[1].
LG190155 drives BMP6 gene transcription and autocrine signaling by activating VDR in MSCs, thereby enhancing the synthesis and secretion of IL-6^[1]. In Vivo:LG190155-pretreated LMSCs (1×10⁶ cells per mouse; tail vein injection; once weekly; continued until day 28) significantly extends the median overall survival of AML-bearing NOD-SCID mice to 48 days and reduces the leukemia cell burden in their peripheral blood, bone marrow, liver and spleen^[1].